Sodium zirconium cyclosilicate in hyperkalemia

New England Journal of Medicine

Volumn 372, Issue 3, 2015, Pages 222-231

  Packham, David K ^a,b   Rasmussen, Henrik S ^c,d   Lavin, Philip T ^g   El Shahawy, Mohamed A ^h   Roger, Simon D ^c   Block, Geoffrey ^j   Qunibi, Wajeh ^e   Pergola, Pablo ^f   Singh, Bhupinder ^d,i  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c Renal Research   (Australia)

^d ZS Pharma   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^f Renal Assocs   (United States)

^g Boston Biostatistics Research Foundation   (United States)

^h Medical Research Institute   (United States)

ⁱ Apex Research   (United States)

^j Denver Nephrologists   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SODIUM ZIRCONIUM CYCLOSILICATE; POTASSIUM; SILICATE;

AGED; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG WITHDRAWAL; EDEMA; ELEVATED BLOOD PRESSURE; FEMALE; GLOMERULUS FILTRATION RATE; HEART ARRHYTHMIA; HUMAN; HYPERKALEMIA; HYPOKALEMIA; INTENTION TO TREAT ANALYSIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; POTASSIUM BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; ADULT; BLOOD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DIABETES COMPLICATIONS; DISEASE FREE SURVIVAL; DRUG EFFECTS; HEART FAILURE; MIDDLE AGED; PROSPECTIVE STUDY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SECONDARY PREVENTION;

ADULT; AGED; DIABETES COMPLICATIONS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE; HUMANS; HYPERKALEMIA; MALE; MIDDLE AGED; POTASSIUM; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM; SECONDARY PREVENTION; SILICATES;

EID: 84920973726     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1411487     Document Type: Article

References (31)

1. Khanagavi J, Gupta T, Aronow WS, et al. Hyperkalemia among hospitalized patients and association between duration of hyperkalemia and outcomes. Arch Med Sci 2014;10:251-7.
2. An JN, Lee JP, Jeon HJ, et al. Severe hyperkalemia requiring hospitalization: predictors of mortality. Crit Care 2012;16: R225.
3. Jain N, Kotla S, Little BB, et al. Predictors of hyperkalemia and death in patients with cardiac and renal disease. Am J Cardiol 2012;109:1510-3.
4. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev 2009;3:CD007004.
5. Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atar D. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J Card Fail 2004;10:297-303.
6. Ahn SY, Ryu J, Baek SH, et al. Incident chronic kidney disease and newly developed complications related to renal dysfunction in an elderly population during 5 years: a community-based elderly population cohort study. PLoS One 2013;8(12):e84467.
7. Tylicki L, Lizakowski S, Rutkowski B. Renin-angiotensin-aldosterone system blockade for nephroprotection: current evidence and future directions. J Nephrol 2012;25:900-10.
8. Palmer BF, Fenves AZ. Optimizing blood pressure control in patients with chronic kidney disease. Proc (Bayl Univ Med Cent) 2010;23:239-45.
9. Berl T. Review: renal protection by inhibition of the renin-angiotensin-aldosterone system. J Renin Angiotensin Aldosterone Syst 2009;10:1-8.
10. St Peter WL, Odum LE, Whaley-Connell AT. To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease. Pharmacotherapy 2013;33:496-514.
11. Estacio RO. Renin-angiotensin-aldosterone system blockade in diabetes: role of direct renin inhibitors. Postgrad Med 2009;121:33-44.
12. Stojiljkovic L, Behnia R. Role of renin angiotensin system inhibitors in cardiovascular and renal protection: a lesson from clinical trials. Curr Pharm Des 2007; 13:1335-45.
13. McCullough PA, Beaver TM, Bennett-Guerrero E, et al. Acute and chronic cardiovascular effects of hyperkalemia: new insights into prevention and clinical management. Rev Cardiovasc Med 2014;15:11-23.
14. Vardeny O, Claggett B, Anand I, et al. Incidence, predictors and outcomes related to hypo-and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. Circ Heart Fail 2014;7:573-9.
15. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.
16. Yang A, Leon A, Nuttall M, Low J, Rasmussen H. In vitro ion exchange capacity and selectivity of ZS-9, a novel, selective cation trap for the treatment of hyperkalemia. Adv Chronic Kidney Dis 2014;21:247.
17. Ash SR, Singh B, Lavin PT, Stavros F, Rasmussen HS. Safety and efficacy of ZS 9, a novel selective cation trap, for treatment of hyperkalemia in patients with chronic kidney disease. Kidney Int (in press).
18. Dmitrienko A, Tamhane AC, Wang X, Chen X. Stepwise gatekeeping procedures in clinical trial applications. Biom J 2006; 48:984-9
19. Erratum, Biom J 2006;48:1041.
20. Sterns RH, Rojas M, Bernstein P, Chennupati S. Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? J Am Soc Nephrol 2010; 21:733-5.
21. Castillo-Cejas MD, De-Torres-Ramírez I, Alonso-Cotoner C. Colonic necrosis due to calcium polystyrene sulfonate (Kalimate) not suspended in sorbitol. Rev Esp Enferm Dig 2013;105:232-4.
22. Harel Z, Harel S, Shah PS, Wald R, Perl J, Bell CM. Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. Am J Med 2013;126(3):264. e9-264. e24.
23. Tongyoo A, Sriussadaporn E, Limpavitayaporn P, Mingmalairak C. Acute intestinal obstruction due to Kalimate, a potassium-lowering agent: a case report and literature review. J Med Assoc Thai 2013;96:1617-20.
24. Yuan CM, Nee R, Little DJ, Abbott KC. Incidence of sodium polystyrene sulfonate-associated colonic necrosis. Am J Med 2013;126:e13.
25. Watson MA, Baker TP, Nguyen A, et al. Association of prescription of oral sodium polystyrene sulfonate with sorbitol in an inpatient setting with colonic necrosis: a retrospective cohort study. Am J Kidney Dis 2012;60:409-16.
26. Goraya N, Simoni J, Jo CH, Wesson DE. Treatment of metabolic acidosis in patients with stage 3 chronic kidney disease with fruits and vegetables or oral bicarbonate reduces urine angiotensinogen and preserves glomerular filtration rate. Kidney Int 2014;86:1031-8.
27. Goraya N, Simoni J, Jo CH, Wesson DE. A comparison of treating metabolic acidosis in CKD stage 4 hypertensive kidney disease with fruits and vegetables or sodium bicarbonate. Clin J Am Soc Nephrol 2013;8:371-81.
28. Dunkler D, Dehghan M, Teo KK, et al. Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus. JAMA Intern Med 2013;173:1682-92.
29. Aaron KJ, Sanders PW. Role of dietary salt and potassium intake in cardiovascular health and disease: a review of the evidence. Mayo Clin Proc 2013;88:987-95.
30. Goraya N, Wesson DE. Dietary management of chronic kidney disease: protein restriction and beyond. Curr Opin Nephrol Hypertens 2012;21:635-40.
31. Uribarri J, Oh MS. The key to halting progression of CKD might be in the produce market, not in the pharmacy. Kidney Int 2012;81:7-9.